In today’s ACT Brief, we explore how Eli Lilly’s orforglipron could become the first oral GLP-1 therapy reviewed under FDA’s new national priority program, and examine emerging regulatory and ethical ...
Welcome to this special recap of this year’s SCRS Global Site Solutions Summit, where industry leaders gathered to share insights on strengthening collaboration between sponsors, CROs, and sites. The ...
Explore how AstraZeneca’s immuno-oncology strategy focuses on improving survival in hard-to-treat cancers and moving checkpoint inhibitors into curative-intent settings.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback